Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
28,248,974
-
Total 13F shares
-
24,727,156
-
Share change
-
+3,653,975
-
Total reported value
-
$725,109,733
-
Put/Call ratio
-
2.7%
-
Price per share
-
$29.31
-
Number of holders
-
113
-
Value change
-
+$107,969,187
-
Number of buys
-
76
-
Number of sells
-
31
Institutional Holders of LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share (LENZ) as of Q2 2025
As of 30 Jun 2025 LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share (LENZ) had 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 24,727,156 shares of stock of the company.
Largest 10 holders included RA CAPITAL MANAGEMENT, L.P., Alpha Wave Global, LP, Paradigm Biocapital Advisors LP, BlackRock, Inc., VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., 72 Investment Holdings, LLC, SECTORAL ASSET MANAGEMENT INC, TANG CAPITAL MANAGEMENT LLC, and UBS Group AG.
This table shows 113 institutional shareholders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.